UA100840C2 - Композиция для лечения вирусного гепатита - Google Patents

Композиция для лечения вирусного гепатита

Info

Publication number
UA100840C2
UA100840C2 UAA200810179A UAA200810179A UA100840C2 UA 100840 C2 UA100840 C2 UA 100840C2 UA A200810179 A UAA200810179 A UA A200810179A UA A200810179 A UAA200810179 A UA A200810179A UA 100840 C2 UA100840 C2 UA 100840C2
Authority
UA
Ukraine
Prior art keywords
viral hepatitis
treatment
composition
hepatitis
methods
Prior art date
Application number
UAA200810179A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Жан-Франсуа Россинель
Original Assignee
РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си. filed Critical РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си.
Publication of UA100840C2 publication Critical patent/UA100840C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA200810179A 2006-01-09 2007-01-09 Композиция для лечения вирусного гепатита UA100840C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (1)

Publication Number Publication Date
UA100840C2 true UA100840C2 (ru) 2013-02-11

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810179A UA100840C2 (ru) 2006-01-09 2007-01-09 Композиция для лечения вирусного гепатита

Country Status (17)

Country Link
US (3) US8633230B2 (enExample)
EP (1) EP1976516B9 (enExample)
JP (2) JP5185826B2 (enExample)
CN (1) CN101448497B (enExample)
AP (1) AP2907A (enExample)
AU (1) AU2007204963B2 (enExample)
BR (1) BRPI0706379A2 (enExample)
CA (1) CA2636527C (enExample)
DK (1) DK1976516T3 (enExample)
EA (1) EA015560B1 (enExample)
ES (1) ES2422556T3 (enExample)
IL (1) IL192548A (enExample)
MX (1) MX2008008723A (enExample)
NZ (1) NZ569507A (enExample)
UA (1) UA100840C2 (enExample)
WO (1) WO2007081974A2 (enExample)
ZA (1) ZA200806310B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
ES2422556T3 (es) * 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
KR20100056479A (ko) * 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
EA029018B1 (ru) * 2009-02-13 2018-01-31 Ромарк Лабораториз Л.С. Фармацевтические составы нитазоксанида с контролируемым высвобождением
ES2528946T3 (es) 2009-03-20 2015-02-13 University Of Virginia Patent Foundation Benzotiofeno-nitrotiazolida y otros antimicrobianos de amplio espectro
AP3074A (en) 2009-05-12 2014-12-31 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CA2968113C (en) 2009-06-26 2019-05-14 Romark Laboratories L.C. Compounds and methods for treating influenza
WO2012040170A2 (en) 2010-09-20 2012-03-29 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) * 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
AU2015346413B2 (en) 2014-11-11 2019-08-29 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
US20180098972A1 (en) 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
MX381896B (es) 2016-03-31 2025-03-13 Romark Laboratories Lc Compuestos de tiazolida para el tratamiento de infecciones virales.
ES2839453T3 (es) * 2016-04-11 2021-07-05 Genfit Métodos para el tratamiento de enfermedades colestásicas y fibróticas
EP3442952A1 (en) * 2016-04-11 2019-02-20 Genfit Methods of treatment of cholestasis and fibrosis
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3573957B1 (en) 2017-01-24 2023-04-26 Rivara, Mirko Compositions and methods for blocking sodium channels
JP7224294B2 (ja) * 2017-01-27 2023-02-17 ジェンフィ 組合せ療法のための医薬組成物
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
CN111465393A (zh) 2017-11-17 2020-07-28 休伯特·科斯特 用于淋巴管平滑肌瘤和其它疾病的[2-[(5-硝基-1，3-噻唑-2-取代基)氨基甲酰基]苯基]乙酸酯
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
EP3952868B1 (en) * 2019-04-09 2025-08-13 Genfit Combinations of nitazoxanide or tizoxanide and elafibranor for the treatment of primary biliary cholangitis- or primary sclerosing cholangitis-associated inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
WO2022046622A1 (en) 2020-08-24 2022-03-03 Romark Laboratories L.C. Use of thiazolides against coronaviruses
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
PL186504B1 (pl) * 1994-04-13 2004-01-30 Romark Lab Pochodne benzamidowe i kompozycje farmaceutyczne zawierające te pochodne
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DK1222921T3 (da) 1997-05-07 2005-03-07 Romark Lab Lc Farmaceutiske sammensætninger indeholdende tizoxanid og/eller nitazoxanid
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
CN1230198C (zh) * 1998-05-15 2005-12-07 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
US5925622A (en) 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
CN100438868C (zh) 2002-10-29 2008-12-03 科学与工业研究委员会 天然来源的葡萄糖苷酶抑制剂
KR20060054174A (ko) * 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
CA2604640A1 (en) 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
ES2422556T3 (es) * 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
EA029018B1 (ru) * 2009-02-13 2018-01-31 Ромарк Лабораториз Л.С. Фармацевтические составы нитазоксанида с контролируемым высвобождением

Also Published As

Publication number Publication date
AU2007204963A1 (en) 2007-07-19
CA2636527C (en) 2016-05-17
US20140112888A1 (en) 2014-04-24
JP2010070566A (ja) 2010-04-02
USRE47404E1 (en) 2019-05-28
BRPI0706379A2 (pt) 2011-03-22
AP2008004550A0 (en) 2008-08-31
EP1976516A2 (en) 2008-10-08
CN101448497A (zh) 2009-06-03
AU2007204963B2 (en) 2012-09-27
EA200870164A1 (ru) 2008-12-30
US20070167504A1 (en) 2007-07-19
WO2007081974A2 (en) 2007-07-19
ZA200806310B (en) 2009-12-30
AP2907A (en) 2014-05-31
NZ569507A (en) 2011-11-25
MX2008008723A (es) 2008-09-26
DK1976516T3 (da) 2013-07-15
JP5185826B2 (ja) 2013-04-17
EP1976516A4 (en) 2009-11-11
EP1976516B9 (en) 2013-10-30
EA015560B1 (ru) 2011-08-30
HK1123733A1 (en) 2009-06-26
JP2009522371A (ja) 2009-06-11
ES2422556T3 (es) 2013-09-12
WO2007081974A3 (en) 2008-01-17
EP1976516B1 (en) 2013-04-24
CN101448497B (zh) 2013-07-10
US8633230B2 (en) 2014-01-21
US9107913B2 (en) 2015-08-18
CA2636527A1 (en) 2007-07-19
IL192548A0 (en) 2009-02-11
IL192548A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
UA100840C2 (ru) Композиция для лечения вирусного гепатита
IL196815A0 (en) Hepatitis c virus inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
ZA201005700B (en) Hepatitis c virus inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
TW200635596A (en) Pyridazinone compounds
EA200900298A1 (ru) Ингибиторы вируса гепатита с
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
TW200745004A (en) Novel compounds, their preparation and use
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010021717A3 (en) Hcv protease inhibitors
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
TW200734306A (en) Novel compounds, their preparation and use